Pieris Pharma (PIRS) Reports In-Line Q2 Loss

Pieris Pharma (NASDAQ: PIRS) reported Q2 EPS of ($0.14), in-line with the analyst estimate of ($0.14). Revenue for the quarter came in at $1.07 million versus the consensus estimate of $300 thousand.

For earnings history and earnings-related data on Pieris Pharma (PIRS) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Toll Brothers (TOL) Tops Q3 EPS by 5c, reaffirms guidance
• Evolution Petroleum launches stock offering to fund Permian Basin deal